Multidrug-resistant tuberculosis in children: Are the same therapy options available worldwide?
Open Access
- 21 March 2023
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 130, S16-S19
Abstract
No abstract availableKeywords
Funding Information
- QIAGEN
This publication has 17 references indexed in Scilit:
- A Trial of a Shorter Regimen for Rifampin-Resistant TuberculosisNew England Journal of Medicine, 2019
- Launching the Global TB NetworkThe International Journal of Tuberculosis and Lung Disease, 2019
- The burden of multidrug-resistant tuberculosis in childrenThe International Journal of Tuberculosis and Lung Disease, 2018
- The global burden of tuberculosis mortality in children: a mathematical modelling studyThe Lancet Global Health, 2017
- Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic reviewJournal of Thoracic Disease, 2017
- Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewInternational Journal of Molecular Sciences, 2017
- Global burden of drug-resistant tuberculosis in children: a mathematical modelling studyThe Lancet Infectious Diseases, 2016
- Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challengesEuropean Respiratory Journal, 2016
- Short-course treatment for multidrug-resistant tuberculosis: the STREAM trialsEuropean Respiratory Review, 2016
- Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimatesThe Lancet, 2014